Global Human Microbiome Market Report 2022: Rising Focus on the Development of Therapeutics Driving Growth
November 02, 2022 06:03 ET
|
Research and Markets
Dublin, Nov. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type,...
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
November 01, 2022 08:00 ET
|
Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
October 31, 2022 08:00 ET
|
Intrinsic Medicine
Intrinsic’s pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform...
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
October 24, 2022 08:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
2022 Microbiome Market Trends Report Featuring BGI, Chr. Hansen, DuPont, Enterome, Evelo Bio, Gallinee, Ginkgo Bioworks, Illumina, L'Oreal, Morinaga, Nestle, Probi, Rebiotix, Seres, Vedanta, Yakult
October 24, 2022 07:03 ET
|
Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "2022 Microbiome Market Trend" report has been added to ResearchAndMarkets.com's offering. Advances in research have shown that many diseases and...
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 20, 2022 17:15 ET
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Human Microbiome Global Market Report 2022: Featuring 4D Pharma, BiomX, Second Genome, Vedanta Biosciences, DayTwo & More
October 18, 2022 07:48 ET
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Human Microbiome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 13, 2022 08:00 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
October 11, 2022 08:00 ET
|
Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
Axial Therapeutics to Present at BioJapan Conference
October 06, 2022 08:00 ET
|
Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...